The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...
Jan 8, 2019
0
4
Epstein-Barr Virus (EBV) doesn't directly cause cancer, but infection with this common herpes virus brings an increased risk of some cancers, including fast-growing lymphomas. This week in mSphere, researchers report on a ...
Aug 22, 2018
0
15
Children and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big impact.
Jan 2, 2023
0
4
Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor ...
Aug 15, 2016
0
0
Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...
Jan 15, 2013
0
0
A new study led by researchers at Sweden's Karolinska Institutet and Nanyang Technological University in Singapore, provides experimental evidence that a drug that inhibits the EphB-signaling pathway in the cell effectively ...
Apr 1, 2015
1
67
(HealthDay)—Osimertinib is more effective than platinum-pemetrexed therapy in patients with T790M-positive advanced non-small-cell lung cancer whose disease has progressed during first-line epidermal growth factor receptor ...
Dec 8, 2016
0
0
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence ...
Jan 15, 2013
0
0
Manchester scientists have genetically mapped the cancer of a leukaemia patient whose disease was resistant to treatment in order to identify a method of personalising therapy for individuals.
Jul 14, 2015
0
13
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...
Mar 2, 2012
0
0
